Cesca Therapeutics Inc. (KOOL): Investors Should Ignore the Haters And Buy

As volatility creeps into Cesca Therapeutics Inc. (NASDAQ:KOOL), investors need to pay close attention to to the factors affecting stock today as its shares are trading 5.88% or 0.3 points up from last closing price of $5.1, reaching $5.4 at last check. The KOOL share price is gaining for the second day in a row and has risen in 4 of the last 5 days and is up 74.66% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 15,337 shares, and in total 129537 shares valued at $699500 were seen changing hands compared with 114200 shares valued at $582420 recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the KOOL stock.

Cesca Therapeutics Inc. (KOOL) shares have notched a 3-month gain of about 74.66%, but has still advanced 91.08% year to date. By comparison, the stock added 25.71% over the past 12 months, while it jumped 59.58% over the 1 month. The company’s market cap is around $12.19M, with its short interest ratio standing at 0.26%.

In the current trading session for KOOL, the stock witnessed two major price actions, it rose to a high of $5.58 and was down as much as $5 at one point. The high recorded is very low when compared to their 52-week high which is $2.1. The 52-week high is now at 5.19 distance from current price. Their recent low of $5.2 represents a 160.48% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for KOOL is $6.5, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Cesca Therapeutics Inc. earned $-5.25 per share in the trailing 12 months and has a P/E ratio of -1.03. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 60.45 and lower compared to the sector’s average of 30.72. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. KOOL also has P/S multiple of 0.99. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 0.93x.

KOOL‘s last price was up 75.45% as compared to the average trading price of 50 days recorded at $3.08 while enlarging the period to 200 trading days, the average closing price was $3.29. At present, there are 2.39 million in the total number of common shares owned by the public and among those 1.73 million shares have been available to trade. The percentage of shares being held by the company management was 30.91% while institutions stake was 3.1%. The company has generated negative returns on equity over the last 12 months (-147.9%). It managed to keep its gross profit margin at 35.9% over the past 12 months.

When assessing the full upside of the KOOL stock, there is another set of technicals that should be looked into and considered. Its 46.37% gain from moving average of $3.69 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.03 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Cesca Therapeutics Inc. — 1 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $6.5 on shares of Cesca Therapeutics Inc. (NASDAQ:KOOL), which corresponds to 20.37% upside potential than its current market price of $5.4 and implies potential despite the recent advance in the price. However, their current target price has fallen from $6.5 a month ago and is up handily from the consensus target of $1 a quarter ago.

In the last five years, the EPS of the company has been roughly 21.3%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -9.6 over the last five years. The company recently recorded an increase of 115%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards KOOL stock. BlackRock Inc. trimmed position in the company after it dumped -90% or 144,230 shares of its common stock. The hedge fund now owns 14,423 shares worth $77,884, SEC documents show. Vanguard Group Inc cut assets in the stock as 128150.8 shares have been sold, reducing its stake by -26.4% to 94,319 shares which are currently valued at $509,323. In addition, Sabby Management LLC recently reported that it now owns 111,094 shares making a total of $599,908 based on the recent price. This refelects a change of -94.8% in their ownership.